术前强化阿托伐他汀治疗联合充分水化对择期冠状动脉介入术后并发造影剂肾病的影响

《术前强化阿托伐他汀治疗联合充分水化对择期冠状动脉介入术后并发造影剂肾病的影响》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089m学号或申请号B159HebeiMedicalUniversity硕士学位论文在职科学学位术前强化阿托伐他汀治疗联合充分水化对择期冠状动脉介入术后并发造影剂肾病的影响学位申请人：王德良导师：马景涛副教授专业：内科学二级学院：第四医院2015年3月河北医科大学学位论文使用授权及知识产权归属承诺本学位论文在导师(或指导小组)的指导下，由本人独立完成。本学位论文研究所获得的研究成果，其知识产权归河北医科大学所有。河北医科大学有权对本学位论文进行交流、公开和使用。凡发表与学位论文主要内容相关的论文，第一署名为单

2、位河北医科大学，试验材料、原始数据、申报的专利等知识产权均归河北医科大学所有。否则，承担相应法律责任。研究生签名：导师签章_二级学院领导盖章：年/月日河北医科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果，除了文中特别加以标注和致谢等内容外,文中不包含其他人已经发表或撰写的研究成果,指导教师对此进行了审定。本论文由本人独立撰写,文责自负。研究生签名：导师签章：年I月>广曰目录中文摘要························································

3、·····················1英文摘要·············································································5研究论文术前强化阿托伐他汀治疗联合充分水化对择期冠状动脉介入术后并发造影剂肾病的影响前言·············································································10材料与方法·································

4、···································11结果·············································································13附图·············································································15附表································································

5、·············19讨论·············································································22结论·············································································24参考文献·······································································24综述心血管介入治疗中造

6、影剂肾病的研究进展··························27致谢···················································································38个人简历·············································································39中文摘要术前强化阿托伐他汀治疗联合充分水化对择期冠状动脉介入术后并发造影剂肾病的影响摘要目的：造影剂肾病(contr

7、astinducednephropathy，CIN)指排除其他肾脏损害因素、使用造影剂后24~48h发生的急性肾功能损害。随着造影剂在现代影像技术和介入诊治中的广泛应用，由造影剂所导致的肾衰竭已成为院内获得性急性肾损害的第3位。随着心血管疾病介入治疗在临床上的广泛应用，CIN的发生率也显著增加。目前水化疗法已成为临床应用中公认有效且广泛应用的预防手段。同时近年有研究表明，在介入治疗前应用阿托伐他汀可减少CIN的发生。本实验通过观察术前强化阿托伐他汀治疗联合充分水化，探讨其对择期冠状动脉介入术后并发造影剂肾病的影响，同时观察高

8、强度他汀对肝转氨酶的影响。方法：选取2014年1月～2014年7月在保定市第二中心医院心内科住院择期行冠脉介入治疗的患者80例。其中男51例，女29例；平均年龄（57.8±9.1岁）。入选患者均需签署知情同意书。入选标准：具有行冠脉造影检查及治疗指征的患者，且患者术前血肌酐（Scr）正常（